Tulissin

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

tulathromycin

Available from:

Virbac S.A.

ATC code:

QJ01FA94

INN (International Name):

tulathromycin

Therapeutic group:

Cattle; Pigs; Sheep

Therapeutic area:

Antibakterijska sredstva za sistemsku uporabu

Therapeutic indications:

Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis susceptible to tulathromycin. Prisutnost bolesti u stadu treba biti uspostavljena prije metafilaktičkog liječenja. Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis susceptible to tulathromycin. Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica susceptible to tulathromycin. Prisutnost bolesti u stadu treba biti uspostavljena prije metafilaktičkog liječenja. The product should only be used if pigs are expected to develop the disease within 2–3 days. Ovce: Liječenje ranih stadija infektivnog pododermitisa (trbuha nogu) povezanih s virulentnim Dichelobacter nodosusom koji zahtijeva sustavno liječenje.

Product summary:

Revision: 3

Authorization status:

odobren

Authorization date:

2020-04-24

Patient Information leaflet

                                35
B.
UPUTA O VMP
36
UPUTA O VMP:
TULISSIN 100 MG/ML OTOPINA ZA INJEKCIJU ZA GOVEDA, SVINJE I OVCE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
VIRBAC
1
ère
avenue 2065m LID
06516 Carros
Francuska
Proizvođači odgovorni za puštanje serije u promet:
VIRBAC
1
ère
avenue 2065m LID
06516 Carros
Francuska
FAREVA
Zone Industrielle,
29 route des Industries
37530 Pocé-sur-Cisse
Francuska
Uputa o VMP mora sadržavati naziv i adresu proizvođača odgovornog
za puštanje dogovorne serije u
promet.
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Tulissin 100 mg/ml otopina za injekciju za goveda, svinje i ovce.
tulatromicin
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Svaki ml sadrži:
DJELATNA TVAR:
Tulatromicin
100 mg
POMOĆNA TVAR:
Monotioglicerol
5 mg
Bistra bezbojna do blago obojena otopina.
4.
INDIKACIJE
Goveda
Liječenje i metafilaksa respiratorne bolesti goveda (
_engl. _
BRD) uzrokovane bakterijama
_Mannheimia haemolytica_
,
_Pasteurella multocida, Histophilus somni _
i mikoplazmom
_Mycoplasma _
_bovis _
osjetljivima na tulatromicin. Prije upotrebe proizvoda treba
ustanoviti prisutnost bolesti u
skupini.
37
Liječenje zaraznog keratokonjunktivitisa goveda (
_engl. _
IBK) uzrokovanog bakterijom
_Moraxella bovis _
osjetljivom na tulatromicin.
Svinje
Liječenje i metafilaksa respiratorne bolesti svinja (
_engl. _
SRD) uzrokovane bakterijama i
mikoplazmama:
_Actinobacillus pleuropneumoniae_
,
_Pasteurella multocida, Mycoplasma _
_hyopneumoniae, Haemophilus parasuis _
i
_Bordetella bronchiseptica _
osjetljivima na tulatromicin.
Prije upotrebe proizvoda treba ustanoviti prisutnost bolesti u
skupini.. Proizvod treba primjenjivati
samo ako se očekuje da će se bolest u svinja razviti unutar 2-3
dana.
Ovce
Liječenje ranih faza zaraznog pododermatitisa (zarazne šepavosti
ovaca) povezanog sa zarazom
_Dichelobacter nodosus _
koji zahtijeva s
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Tulissin 100 mg/ml otopina za injekciju za goveda, svinje i ovce
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaki ml sadrži:
DJELATNA TVAR:
Tulatromicin
100 mg
POMOĆNA TVAR:
Monotioglicerol
5 mg
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Otopina za injekciju.
Bistra bezbojna do blago obojena otopina.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Goveda, svinje i ovce.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Goveda
Liječenje i metafilaksa respiratorne bolesti goveda (
_engl. _
BRD) uzrokovane bakterijama
_Mannheimia haemolytica_
,
_Pasteurella multocida, Histophilus somni _
i mikoplazmom
_Mycoplasma _
_bovis _
koje su osjetljive na tulatromicin. Prije korištenja proizvoda treba
ustanoviti prisutnost bolesti u
skupini.
Liječenje zaraznog keratokonjunktivitisa goveda (
_engl. _
IBK) uzrokovanog bakterijom
_Moraxella bovis _
osjetljivom na tulatromicin.
Svinje
Liječenje i metafilaksa respiratorne bolesti svinja (
_engl. _
SRD) uzrokovane bakterijama i
mikoplazmama:
_Actinobacillus pleuropneumoniae_
,
_Pasteurella multocida, Mycoplasma _
_hyopneumoniae, Haemophilus parasuis _
i
_Bordetella bronchiseptica _
osjetljivima na tulatromicin. Prije
korištenja proizvoda treba ustanoviti prisutnost bolesti u skupini.
Veterinarsko-medicinski proizvod treba primjenjivati samo ako se
očekuje da će se bolest u svinja
razviti unutar 2-3 dana.
Ovce
Liječenje ranih faza zaraznog pododermatitisa (zarazne šepavosti
ovaca) povezanog sa zarazom
_Dichelobacter nodosus _
koji zahtijeva sustavnu terapiju.
4.3
KONTRAINDIKACIJE
Ne primjenjivati u slučaju preosjetljivosti na makrolidne antibiotike
ili na pomoćne tvari.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
3
Unakrsna rezistencija javlja se kod upotrebe s drugim makrolidima. Ne
primjenjivati zajedno sa
anitmikrobnim lijekovima sa sličnim načinom djelovanja poput drugih
makrolida ili linkozamida.
Ovce:
Učinkovitost antimikro
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-12-2021
Public Assessment Report Public Assessment Report Bulgarian 26-06-2020
Patient Information leaflet Patient Information leaflet Spanish 07-12-2021
Public Assessment Report Public Assessment Report Spanish 26-06-2020
Patient Information leaflet Patient Information leaflet Czech 07-12-2021
Public Assessment Report Public Assessment Report Czech 26-06-2020
Patient Information leaflet Patient Information leaflet Danish 07-12-2021
Public Assessment Report Public Assessment Report Danish 26-06-2020
Patient Information leaflet Patient Information leaflet German 07-12-2021
Public Assessment Report Public Assessment Report German 26-06-2020
Patient Information leaflet Patient Information leaflet Estonian 07-12-2021
Public Assessment Report Public Assessment Report Estonian 26-06-2020
Patient Information leaflet Patient Information leaflet Greek 07-12-2021
Public Assessment Report Public Assessment Report Greek 26-06-2020
Patient Information leaflet Patient Information leaflet English 07-12-2021
Public Assessment Report Public Assessment Report English 26-06-2020
Patient Information leaflet Patient Information leaflet French 07-12-2021
Public Assessment Report Public Assessment Report French 26-06-2020
Patient Information leaflet Patient Information leaflet Italian 07-12-2021
Public Assessment Report Public Assessment Report Italian 26-06-2020
Patient Information leaflet Patient Information leaflet Latvian 07-12-2021
Public Assessment Report Public Assessment Report Latvian 26-06-2020
Patient Information leaflet Patient Information leaflet Lithuanian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-12-2021
Public Assessment Report Public Assessment Report Lithuanian 26-06-2020
Patient Information leaflet Patient Information leaflet Hungarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 07-12-2021
Public Assessment Report Public Assessment Report Hungarian 26-06-2020
Patient Information leaflet Patient Information leaflet Maltese 07-12-2021
Public Assessment Report Public Assessment Report Maltese 26-06-2020
Patient Information leaflet Patient Information leaflet Dutch 07-12-2021
Public Assessment Report Public Assessment Report Dutch 26-06-2020
Patient Information leaflet Patient Information leaflet Polish 07-12-2021
Public Assessment Report Public Assessment Report Polish 26-06-2020
Patient Information leaflet Patient Information leaflet Portuguese 07-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 07-12-2021
Public Assessment Report Public Assessment Report Portuguese 26-06-2020
Patient Information leaflet Patient Information leaflet Romanian 07-12-2021
Public Assessment Report Public Assessment Report Romanian 26-06-2020
Patient Information leaflet Patient Information leaflet Slovak 07-12-2021
Public Assessment Report Public Assessment Report Slovak 26-06-2020
Patient Information leaflet Patient Information leaflet Slovenian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 07-12-2021
Public Assessment Report Public Assessment Report Slovenian 26-06-2020
Patient Information leaflet Patient Information leaflet Finnish 07-12-2021
Public Assessment Report Public Assessment Report Finnish 26-06-2020
Patient Information leaflet Patient Information leaflet Swedish 07-12-2021
Public Assessment Report Public Assessment Report Swedish 26-06-2020
Patient Information leaflet Patient Information leaflet Norwegian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 07-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 07-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 07-12-2021

Search alerts related to this product

View documents history